Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.81 |
| ▸ | GAA | P10253 | 7/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.81 |
| ▸ | MAPT | P10636 | 2/20 | 0.81 |
| ▸ | HPGD | P15428 | 2/20 | 0.81 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.81 |
| ▸ | TSHR | P16473 | 1/20 | 0.81 |
| ▸ | CFTR | P13569 | 3/20 | 0.55 |
| ▸ | GLA | P06280 | 2/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | CDC25B | P30305 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30041521 | 0.89 | ALDH1A1 (1.00) | ALDH1A1GAAKDM4EHSD17B10MAPT | |
| SCHEMBL1809277 | 0.89 | ALDH1A1 (1.00) | ALDH1A1GAAKDM4EHSD17B10MAPT | |
| SCHEMBL25230816 | 0.88 | ALDH1A1 (0.73) | ALDH1A1GAAKDM4EHSD17B10MAPT | |
| SCHEMBL14081421 | 0.88 | ALDH1A1 (0.78) | ALDH1A1GAAKDM4EHSD17B10MAPT | |
| SCHEMBL26466965 | 0.86 | ALDH1A1 (0.76) | ALDH1A1GAAKDM4EHSD17B10MAPT | |
| SCHEMBL2387646 | 0.86 | ALDH1A1 (0.64) | ALDH1A1GAAKDM4EHSD17B10MAPT | |
| SCHEMBL12598054 | 0.85 | ALDH1A1 (0.69) | ALDH1A1GAAKDM4EHSD17B10MAPT | |
| SCHEMBL13163983 | 0.85 | ALDH1A1 (0.69) | ALDH1A1GAAKDM4EHSD17B10MAPT | |
| SCHEMBL7649762 | 0.85 | ALDH1A1 (0.73) | ALDH1A1GAAKDM4EHSD17B10MAPT | |
| SCHEMBL15888578 | 0.84 | ALDH1A1 (0.68) | ALDH1A1GAAKDM4EHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109415553-B | Plasticized thermoset resins and related cured resins, curing methods, and articles comprising cured resins | 马萨诸塞大学 | 2022-08-05 | — | — | CN | claimed |
| EP-3481899-A1 | PLASTICIZED THERMOSET RESIN, AND ASSOCIATED CURED RESIN, METHOD OF CURING, AND ARTICLE COMPRISING CURED RESIN | The University of Massachusetts (US) | 2019-05-15 | — | — | EP | claimed |
| WO-2018008003-A1 | PLASTICIZED THERMOSET RESIN, AND ASSOCIATED CURED RESIN, METHOD OF CURING, AND ARTICLE COMPRISING CURED RESIN | THE UNIVERSITY OF MASSACHUSETTS (US) | 2018-01-11 | — | — | WO | claimed |
| CN-119912402-A | FTO inhibitor and preparation method and application thereof | 中国科学院上海药物研究所 | 2025-05-02 | — | — | CN | disclosed |
| US-20230069963-A1 | PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2023-03-09 | — | — | US | disclosed |
| EP-3481899-B1 | PLASTICIZED THERMOSET RESIN, AND ASSOCIATED CURED RESIN, METHOD OF CURING, AND ARTICLE COMPRISING CURED RESIN | UNIV MASSACHUSETTS (US) | 2022-12-21 | — | — | EP | disclosed |
| CN-109415553-B | Plasticized thermoset resins and related cured resins, curing methods, and articles comprising cured resins | 马萨诸塞大学 | 2022-08-05 | — | — | CN | disclosed |
| EP-3903788-A1 | PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND | Taisho Pharmaceutical Co., Ltd. (JP) | 2021-11-03 | — | — | EP | disclosed |
| US-10913844-B2 | Plasticized thermoset resin, and associated cured resin, method of curing, and article comprising cured resin | THE UNIVERSITY OF MASSACHUSETTS (US) | 2021-02-09 | — | — | US | disclosed |
| WO-2020138015-A1 | PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND | 大正製薬株式会社 | 2020-07-02 | — | — | WO | disclosed |
| US-20190309159-A1 | PLASTICIZED THERMOSET RESIN, AND ASSOCIATED CURED RESIN, METHOD OF CURING, AND ARTICLE COMPRISING CURED RESIN | THE UNIVERSITY OF MASSACHUSETTS | 2019-10-10 | — | — | US | disclosed |
| EP-2206707-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-7626039-B2 | Arylpropionamide, arylacrylamide, ayrlpropynamide, or arylmethylurea analogs as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090253766-A1 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090181983-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL -MEYERS SQUIBB COMPANY | 2009-07-16 | — | — | US | disclosed |
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| EP-1963294-A1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| US-20080161373-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB CO. | 2008-07-03 | — | — | US | disclosed |
| WO-2007067613-A1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| US-4873236-A | BRADYCARDIAL AGENTS | DR. KARL THOMAE GMBH (DE) | 1989-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | PTPRS, PTPN5, PTPRR | ALDH1A1 2398/4885GAA 1048/4885KDM4E 2554/4885 |
| US-20080161373-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | TFPI, F11, F12 | ALDH1A1 1874/4885GAA 2920/4885KDM4E 698/4885 |
| US-20090253766-A1 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | TFPI, F12, F11 | ALDH1A1 2061/4885GAA 2393/4885KDM4E 1154/4885 |
| US-20230069963-A1 | PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND | ZC3HAV1, ZC3HAV1L, IL5 | ALDH1A1 2801/4885GAA 4019/4885KDM4E 3411/4885 |
| US-20090181983-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | TFPI, F11, F12 | ALDH1A1 3910/4885GAA 3486/4885KDM4E 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.